Now that we are discussing the possible impact of patent (applications) referring to RVX-208, I think that the (perhaps) most interesting patent application regarding RVX-208 filed by 3rd party ( is the following: http://www.freepatentsonline.com/y2016/0095867.html

It is based on an article that came out some time ago, but the following sentence from the patent application is quite interesting:

"Next a number of structurally diverse BET inhibitors (iBET, iBET-151, RVX-208, PF-1; FIG. 1F) were assessed for their ability to inhibit cardiomyocyte hypertrophy. At equimolar doses, it was found that inhibition of agonist-induced cardiomyocyte hypertrophy was indeed a class effect of BET inhibitors, with the relative potency of these compounds correlating with their known IC50 against BRD4 (Filippakopoulos et al., 2010). "

One of the inventors is James Bradner, the (co-)inventor of JQ1 and founder of Tensha Therapeutics (acquired by Roche for $535M) - here is a link: http://www.fiercebiotech.com/financials/bradner-factor-roche-bags-a-bet-inhibitor-535m-tensha-buyout

Well, just something to think about. Have a nice weekend!

BKVC